Loading page
Start with the latest view of this part of the market. Then see which stock ideas are ready, which promising ideas still need work, and which event could change the answer.
0 ready·3 under review·2 lower-priority
The biotech opportunity set is still rich in dated catalysts but not broadly attractive at a high-conviction long-term bar. The best hunting ground remains funded late-stage companies with primary-source regulatory dates or pivotal readouts where the market is mispricing commercial probability rather than merely assigning binary trial risk. I would avoid thinly financed single-asset stories unless a partnership, cash floor, or post-event overreaction materially changes the downside shape.
No material upgrade versus the prior completed sweep. I rechecked current PDUFA, Q4 readout, obesity/metabolic, oncology, rare-disease, neuroscience, and financing/M&A screens; the quality constraint still controls.
Did a post-cutoff FDA action, pivotal readout, financing, or selloff create a de-risked biotech mispricing?
Facts checked through Aug 28, 2026 · saved Aug 28, 2026
The current biotech opportunity set remains highly catalyst-rich but quality-constrained. The most useful hunting ground is still late-stage, funded issuers with primary-source regulatory dates or imminent pivotal readouts, while weaker balance sheets and binary single-asset stories remain poor fits for an 8/10 fundamentals bar. A better setup would require a clear post-event overreaction, a de-risked approval path, or misunderstood commercial economics.
These ideas passed every required check. The same answer appears on Today, Ideas, and the stock’s own page.
No stock in this area has passed every check yet. Promising ideas remain visible below with the exact work still needed.
Researchers see a strong case, but one or more required checks are unfinished. We show every missing item so a strong story is never mistaken for a ready idea.
Next: open the Idea to see the fact or date we will check.
Next: open the Idea to see the fact or date we will check.
Next: open the Idea to see the fact or date we will check.
FDA PDUFA action date for UX111 in Sanfilippo syndrome Type A (MPS IIIA)
GENGLYCOS launch access and qualified treatment-center rollout indicators after accelerated approval
Q3 2026 earnings — Attruby US net sales print confirming (or breaking) the sequential first-line ramp
ICER Midwest CEPAC public meeting on aldosterone synthase inhibitors for hypertension, including lorundrostat and baxdrostat
FDA PDUFA decision on BBP-418 for LGMD2I/R9 — potential first-ever approved LGMD therapy; priority review, all Phase 3 FORTIFY endpoints met, no AdCom planned
FDA PDUFA target action date for lorundrostat NDA in adult hypertension in combination with other antihypertensive drugs
Initial launch-readiness and label-to-access signals if lorundrostat is approved
Q2 2026 results (Aug 10): cash $792.3M, pro-forma $865.9M after ATM proceeds, funded into late 2028 through approvals and early commercial launch — balance sheet stronger than thesis assumed. Crucially, a third NDA was submitted to FDA on June 30, 2026 for bezuclastinib in advanced SM (AdvSM). Both prior NDA acceptances are clean: GIST PDUFA Nov 30 (no advisory committee, no review issues identified); non-advanced SM PDUFA Dec 30. Three potential approvals from a single asset in one quarter — a scenario the thesis did not fully price. Conviction raised.
Open the Idea for the saved explanation.
Open the Idea for the saved explanation.
Open the Idea for the saved explanation.
Open the Idea for the saved explanation.
Open the Idea for the saved explanation.
Open the Idea for the saved explanation.
Open the Idea for the saved explanation.
Open the Idea for the saved explanation.
Open the Idea for the saved explanation.
Open the Idea for the saved explanation.
No idea has ended in this area yet.
Biotechnology and pharma: oncology, obesity/metabolic, gene editing, rare diseases, neuroscience, immunology, drug-discovery platforms, and clinical-stage companies with dated catalysts (trial readouts, PDUFA decisions, M&A)
A research-strength rating of 8/10 lets an idea enter the public review list; it does not make the idea ready. Readiness also requires a recent review, a saved starting price, an active target, current risk research, a clear way the idea could be proven wrong, dated sources for important claims, all six confidence checks, a usable market price and currency, and a clear next test.